Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2025)

Tarsus Pharmaceuticals (TARS) has 3 years of Finished Goods data on record, last reported at $3.0 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 47.66% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 47.66%, while the annual FY2025 figure was $3.0 million, 47.66% up from the prior year.
  • Finished Goods reached $3.0 million in Q4 2025 per TARS's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $3.0 million in Q4 2025 and bottomed at $182000.0 in Q4 2023.
  • Average Finished Goods over 3 years is $1.7 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Finished Goods: soared 1002.2% in 2024, then surged 47.66% in 2025.
  • A 3-year view of Finished Goods shows it stood at $182000.0 in 2023, then skyrocketed by 1002.2% to $2.0 million in 2024, then skyrocketed by 47.66% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $3.0 million in Q4 2025, $2.8 million in Q3 2025, and $2.3 million in Q2 2025.